CORTEXA
← Browse
openalexFrontiers in Pharmacology2026-07-24Cited by 0

Protective effects and possible mechanisms of matrine-type alkaloids (matrine and oxymatrine) in animal models of ulcerative colitis: a preclinical systematic review and meta-analysis

吕书晴, H W Yang, Shiying Wang, Jiahui Ye, S H. M. Huang, Linkun Cai

Background Matrine and oxymatrine are bioactive alkaloids from Sophora species with reported anti-inflammatory and antioxidant effects in ulcerative colitis (UC). However, their overall efficacy has not been systematically evaluated. Methods Databases including PubMed, EMBASE, Web of Science, Scopus, CNKI, Wanfang, VIP, and SinoMed were searched to January 2026. Animal studies using matrine or oxymatrine monotherapy in UC models were included. Effect sizes were calculated as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Results Thirteen studies were included. Compared with controls, matrine-type alkaloids significantly reduced histopathological scores (SMD = −3.47, 95% CI: −4.83 to −2.11) and decreased Disease Activity Index (DAI) at 3 days (SMD = −2.92, 95% CI: −4.27 to −1.57) and 7 days (SMD = −4.76, 95% CI: −6.30 to −3.23), but not at 14 days (SMD = −1.01, 95% CI: −2.22 to 0.20). Body weight increased at 7 days (SMD = 2.76, 95% CI: 1.95–3.57) and 14 days (SMD = 2.41, 95% CI: 0.12–4.69), and colon length was also increased (SMD = 2.09, 95% CI: 1.55–2.64). Matrine-type alkaloids reduced TNF-α (SMD = −2.88, 95% CI: −3.50 to −2.26), IL-6 (SMD = −2.91, 95% CI: −4.64 to −1.17), IL-1β (SMD = −2.73, 95% CI: −4.27 to −1.19), and MDA levels (SMD = −3.06, 95% CI: −4.47 to −1.65), while increasing SOD activity (SMD = 2.63, 95% CI: 1.37–3.89). Subgroup analyses suggested generally similar directions of effect across species and model types. The pooled effect estimate appeared larger in the oxymatrine subgroup than in the matrine subgroup, but this indirect comparison should be interpreted cautiously. Conclusion Matrine-type alkaloids may exert protective effects in UC animal models by improving histological damage, reducing disease activity, and modulating inflammatory and oxidative stress pathways. These findings suggest their potential as multi-target therapeutic agents, although further high-quality studies are required for clinical translation. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261376235 , identifier CRD420261376235.

View free PDFSource page

Related papers

openalexFrontiers in Pharmacology2026-07-23

Medication adherence and influencing factors in children and adolescents with attention deficit hyperactivity disorder (ADHD): a systematic review and meta-analysis

Jianing Liu, Bingyao Kang, Weiqi Deng, Zilong Hao, Chunsong Yang, Li Zhang

Background Medication non-adherence is widely occurring in children and adolescents with ADHD, which may lead to adverse consequences. However, the pooled adherence rate and influencing factors are inconsistent in different studies. Methods We searched PubMed, Embase (Ovid), Coch…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-24

Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis

Yiheng Liu, B Y Liu, Weiran Dai

Background Conventional dual antiplatelet therapy (DAPT) post percutaneous coronary intervention (PCI) comprises aspirin and a P2Y 12 inhibitor. However, aspirin increases gastrointestinal and bleeding risks. Indobufen, a reversible COX-1 inhibitor, may offer a safer alternative.…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-23

Beyond cardiovascular protection: a conceptual and translational review of the hepato-specific mechanisms of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)

Carolina Jiménez-González, Paula Iruzubieta, Marta Alonso-Peña, Lorena Cayon, Javier Crespo

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, and cardiovascular disease remains the leading cause of death in this population. Statins are therefore a cornerstone of therapy in MASLD because of their antia…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-24

Editorial: Increasing importance of patients-generated real world data for healthcare policy decisions about medicinal products: volume III

Wai Yee Choon, K C Lee, Paul Scuffham, Shu Chuen Li, David Bin-Chia Wu, Jeff J. Guo

Increasing importance of patient-generated real-world data for healthcare policy decisions about medicinal products: Volume III Real-world data (RWD) and the real-world evidence (RWE) derived from it have moved from the margins to the centre of decision-making about medicinal pro…

View free PDFSource page
crossrefFrontiers in Pharmacology2026-07-10

Deciphering tuberculosis pathway mechanisms via graph neural networks and multimodal deep learning: a comprehensive AI-driven framework for precision medicine

Yuanli Yang, Huanqing Liu, Qian Lei, Tingting Li

Background Tuberculosis (TB) remains a global health crisis, with complex molecular mechanisms that are not fully understood. Traditional pathway analysis methods fail to capture the intricate non-linear relationships within biological networks. Methods We developed a novel artif…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-23

Polyphyllin II attenuates renal fibrosis in diabetic kidney disease partly through regulation of autophagy and PI3K/AKT/mTOR signaling

Xia Sun, Xinfang Qin, Huixin Bi

Background Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD) worldwide, and renal fibrosis is a key pathological feature driving disease progression. Polyphyllin II (PPII), a steroidal saponin isolated from Rhizoma Paridis, has shown renoprotectiv…

View free PDFSource page